Tara Stephenson

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Hematology, Immunology +17

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · The Lancet · 2021 · 312 citations

Medicine, Hematology, Immunology +12

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos et al. · Blood Advances · 2023 · 78 citations · Full text

Life Sciences, Hematology, Immunology +17

Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.

Alfred L. Garfall, Ajay K. Nooka, Niels W.C.J. van de Donk et al. · Journal of Clinical Oncology · 2024 · 77 citations

Medicine, Oncology, Pharmacotherapy +16

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

Niels W.C.J. van de Donk, Philippe Moreau, Alfred L. Garfall et al. · Journal of Clinical Oncology · 2023 · 65 citations

Medicine, Oncology, Pharmacotherapy +16